RY

169.48

+0.11%↑

TD

94.14

-0.12%↓

BMO

133.89

+1%↑

BNS

72.41

+0.18%↑

CM

91.45

+0.8%↑

RY

169.48

+0.11%↑

TD

94.14

-0.12%↓

BMO

133.89

+1%↑

BNS

72.41

+0.18%↑

CM

91.45

+0.8%↑

RY

169.48

+0.11%↑

TD

94.14

-0.12%↓

BMO

133.89

+1%↑

BNS

72.41

+0.18%↑

CM

91.45

+0.8%↑

RY

169.48

+0.11%↑

TD

94.14

-0.12%↓

BMO

133.89

+1%↑

BNS

72.41

+0.18%↑

CM

91.45

+0.8%↑

RY

169.48

+0.11%↑

TD

94.14

-0.12%↓

BMO

133.89

+1%↑

BNS

72.41

+0.18%↑

CM

91.45

+0.8%↑

Search

Hercules Capital Inc

Gesloten

SectorFinanciën

18.65 0.27

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

18.47

Max

18.72

Belangrijke statistieken

By Trading Economics

Inkomsten

61M

119M

Verkoop

89M

169M

K/W

Sectorgemiddelde

10.828

26.043

Dividendrendement

8.48

Winstmarge

70.164

Werknemers

100

EBITDA

18M

120M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+7.05% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

8.48%

4.04%

Volgende Winsten

12 feb 2026

Volgende dividenddatum

4 mrt 2026

Volgende Ex Dividend datum

25 feb 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

159M

3.4B

Vorige openingsprijs

18.38

Vorige sluitingsprijs

18.65

Nieuwssentiment

By Acuity

50%

50%

182 / 525 Rangschikking in Finance

Technische score

By Trading Central

Vertrouwen

Neutral Evidence

Hercules Capital Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

12 jan 2026, 23:54 UTC

Marktinformatie

CBA Could Underperform Again in 2026 -- Market Talk

12 jan 2026, 23:48 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

12 jan 2026, 23:48 UTC

Marktinformatie

Nikkei May Rise on Weaker Yen -- Market Talk

12 jan 2026, 23:43 UTC

Marktinformatie

Gold Edges Lower on Likely Technical Correction -- Market Talk

12 jan 2026, 23:18 UTC

Acquisities, Fusies, Overnames

Paramount Sues Warner Bros., Plans Proxy Fight. The Ellisons Aren't Giving Up. -- Barrons.com

12 jan 2026, 21:56 UTC

Marktinformatie

Light & Wonder Gets Positive Outcome From Lawsuit -- Market Talk

12 jan 2026, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

12 jan 2026, 21:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

12 jan 2026, 21:50 UTC

Marktinformatie
Winsten

Auto & Transport Roundup: Market Talk

12 jan 2026, 21:18 UTC

Marktinformatie

Global Equities Roundup: Market Talk

12 jan 2026, 21:18 UTC

Marktinformatie

Pfizer CEO Sees Large Cash Market for Obesity Drugs -- Market Talk

12 jan 2026, 20:54 UTC

Winsten

Gap, Fortinet, and More Stocks That Usually Outperform After Earnings -- Barrons.com

12 jan 2026, 20:48 UTC

Marktinformatie

Oil Futures Settle Higher in Choppy Trade -- Market Talk

12 jan 2026, 20:33 UTC

Marktinformatie

U.S. Natural Gas Jumps on Colder Weather Outlook -- Market Talk

12 jan 2026, 20:18 UTC

Acquisities, Fusies, Overnames

Credit Agricole Sees Banco BPM Stake Helping 2025 Net by EUR200M >ACA.FR

12 jan 2026, 20:18 UTC

Acquisities, Fusies, Overnames

Credit Agricole: European Central Bank Approves Crossing of 20% Threshold in Share Capital of Banco BPM

12 jan 2026, 19:39 UTC

Marktinformatie

J&J CEO: Trump Pact Allows Company to Focus on Core Operations -- Market Talk

12 jan 2026, 19:36 UTC

Marktinformatie

Gold and Silver Set New Records on Fed Probe -- Market Talk

12 jan 2026, 19:36 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

12 jan 2026, 19:33 UTC

Marktinformatie

Venezuela's 'Proven' Oil Reserves Raises Questions -- Market Talk

12 jan 2026, 19:24 UTC

Acquisities, Fusies, Overnames

Dynavax: 'Party A' CEO Sent a Non-Binding $15/Shr Proposal on Dec. 23

12 jan 2026, 19:22 UTC

Acquisities, Fusies, Overnames

Dynavax Files Tender Offer Recommendation Statement Related to Sanofi Deal, Mentions Talks With 'Party A'

12 jan 2026, 18:21 UTC

Acquisities, Fusies, Overnames

Paramount Plans Proxy Fight to Push Hostile Warner Bid -- 2nd Update

12 jan 2026, 18:20 UTC

Acquisities, Fusies, Overnames

This French Biotech Stock Surged 1,700% in 2025. Eli Lilly Is Taking an Interest. -- Barrons.com

12 jan 2026, 18:19 UTC

Marktinformatie

Modest Canadian Economic Impact Seen from Venezuela Changes -- Market Talk

12 jan 2026, 18:16 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Comcast Could Unlock Value With a Spinoff of NBCUniversal Assets, Analysts Say -- Market Talk

12 jan 2026, 18:09 UTC

Marktinformatie

Global Equities Roundup: Market Talk

12 jan 2026, 18:09 UTC

Marktinformatie

Baidu's Outlook Bodes Well For Shares -- Market Talk

12 jan 2026, 18:01 UTC

Acquisities, Fusies, Overnames

QXO Is Raising Another $1.8 Billion for Its M&A War Chest -- Barrons.com

12 jan 2026, 18:00 UTC

Marktinformatie

Canada's 'Breakeven' Employment Recalibrating -- Market Talk

Peer Vergelijking

Prijswijziging

Hercules Capital Inc Prognose

Koersdoel

By TipRanks

7.05% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 20.04 USD  7.05%

Hoogste 24 USD

Laagste 18 USD

Gebaseerd op 7 Wall Street-analisten die 12-maands prijsdoelen bieden voor Hercules Capital Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

7 ratings

6

Buy

1

Hold

0

Sell

Technische score

By Trading Central

17.41 / 17.93Steun & Weerstand

Korte Termijn

Neutral Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

182 / 525 Rangschikking in Financiën

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Hercules Capital Inc

Hercules Capital, Inc. is a business development company. The firm specializing in providing private equity, venture debt, and growth capital to privately held venture capital-backed companies at all stages of development from mid venture to expansion stage including select publicly listed companies and select special opportunity companies that require additional capital to fund acquisitions, recapitalizations and refinancing and established-stage companies. The firm provides growth capital financing solutions for capital extension; management buy-out and corporate spin-out financing solutions; company, asset specific, or intellectual property acquisition financing; convertible, subordinated and/or mezzanine loans; domestic and international corporate expansion; vendor financing; revenue acceleration by sales and marketing development, and manufacturing expansion. It provides asset-based financing with a focus on cash flow; accounts receivable facilities; equipment loans or leases; equipment acquisition; facilities build-out and/or expansion; working capital revolving lines of credit; inventory. The firm also provides bridge financing to IPO or mergers and acquisitions or technology acquisition; dividend recapitalizations and other sources of investor liquidity; cash flow financing to protect against share price volatility; competitor acquisition; pre-IPO financing for extra cash on the balance sheet; public company financing to continue asset growth and production capacity; short-term bridge financing; and strategic and intellectual property acquisition financings. It also focuses on customized financing solutions, emerging growth, mid venture, and late venture financing. The firm invests primarily in structured debt with warrants and, to a lesser extent, in senior debt and equity investments. The firm generally seeks to invest in companies that have been operating for at least six to 12 months prior to the date of their investment. It prefers to invest in technology, SaaS Finance, energy technology, sustainable
help-icon Live chat